



MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, February 11, 2016
7:15 a.m. to 8:15 a.m.
Cannon Health Building
Room 125

Board Members Present:

Jay Aldus, D.D.S	Jennifer Brinton, M.D., Board Chair
Ben Berrett, Pharm.D.	Susan Siegfried, M.D.
Neal Catalano, Pharm.D	Kumar Shah, M.Sc., P.Eng.
Holly Gurgle, Pharm.D.	Katherine Smith, Pharm.D.
Steve Lore, M.D.	Michael Symond, M.D.
Keith Tolman, M.D.	

Board Members Excused:

N/A

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, PharmD	Heather Santacruz, R.N.
Robyn Seely, PharmD	Merelynn Berrett, R.N
Bryan Larson, PharmD	Alyssa Pitts, R.N.
Megan Schlappi, CPhT	

Other Individuals Present:

Gary Oderda, University of Utah	Kylan Brown, State Auditor
Joanita Lake, University of Utah	Paul Skodny, Amgen
Barbara Boner, Novartis	Charissa Anne, Johnson & Johnson
Cody Ball, Select Heath	Jon Bloomfield, Jazz Pharma
Lynsey Spence, State Auditor	Caroline E. Kicklighter, Novartis
Kelly Ponce, AstraZeneca	

Meeting conducted by: Robyn Seely, Pharm. D.

- Welcome & Housekeeping:** Jennifer Brinton opened the meeting.
- Review and Approval of October Minutes:** Keith Tolman made a motion to approve the January meeting minutes. Kumar Shah seconded the motion. All in favor.
- Skeletal Muscle Relaxants, Grastek, Ragwitek and Oralair- 9 month review:** Robyn Seely said that the previously set criteria on these medications is working

well with no problems.

4. **Entresto:** Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about the three androgen products. Data was also presented about the utilization of the drugs in the Utah Medicaid population.
5. **Public Comments:** Caroline E. Kicklighter asked the board to reconsider some of their drafted PA criteria. She also offered to answer any of the board's questions.

6. **Board Discussion**

- a. Mike Symond asked what the utilization was for Entresto. Joanita Lake said there is only one Medicaid patient currently on Entresto. Because of the low utilization, Mike Symond, Keith Tolman and Steve Lore all disagreed on creating prior authorization criteria.
- b. Keith Tolman said that putting strict criteria on this medication will only increase the cost of health care. He also disagreed with the P.A draft criteria that wanted documentation of reduced left ventricular ejection fraction $\leq 35\%$.
- c. Susan Siegfroid and Holly Gurgle disagreed with Keth Tolman. Holly Gurgle said that it was important to follow the $\leq 35\%$ because that is the criteria that all of the clinical trials used and it also states it in the package insert for Entresto. She also worried that if we do not keep that criteria in, prescribers may use Entresto off label (for hypertension only).
- d. Steve Lore disagreed with Holly Gurgle wanting to keep the reduced left ventricular ejection fraction $\leq 35\%$ in the pa criteria. He said that treating real life patients is completely different than the clinical lab trials and, therefore, it does not make sense to keep the clinical trials criteria.
- e. Kumar Shah asked how accurate the tests were when trying to see if there was reduced left ventricular ejection fraction. Steve Lore said the tests accuracy is very poor. He said that there are two different testing measures and they usually differ in their accuracy and precision.
- f. Keith Tolman asked what the repercussions would be of not having criteria for this medication. Chad Hope said that there should be criteria, but it could be very simple with no specific numbers that a patient would have to meet.
- g. Neal Catalano asked if the board would be willing to keep the criteria relating to ejection fraction, but remove the $\leq 35\%$. Keith Tolman asked again why there needs to be any criteria at all. Holly Gurgle answered and said there's not enough long term data to just let the drug out there and allow prescribers to use it off label.
- h. Katherine Smith made a motion to see if there should be pa criteria at all. Holly Gurgle seconded the motion. Keith Tolman and Mike Symond dissented. The motion passed.
- i. Susan Siegfroid asked if the board could keep the pa criteria relating to pregnancy, as Entresto has a black box warning. Keith Tolman disagreed, saying the doctors will know what is going on with their patient and there is no reason that the nurses should have to ask each time if the patient is pregnant. Chad hope stated that there is something called DUR edits that the pharmacy will see to help with the pregnancy issue.
- j. Jennifer Brinton told the board that their time was up. She asked if they

wanted to make any motions now, or carry this discussion on to the next month's meeting.

- k. Holly Gurgle made a motion to include the wording of the criteria to say "systolic or reduced left ejection fraction" with no specific, required number associated. Neal Catalano seconded. All in favor.
- l. Neal Catalano made a motion to accept the drafted criteria. Ben Berrett seconded the motion. All in favor.

7. Meeting Adjourned

Jennifer Britton motioned to close the meeting. Neal Catalano seconded. All in favor.

8. Next meeting is scheduled for March 10th, 2016.

Minutes prepared by Megan Schlappi, CPhT

Recording available upon request, send email to medicaidpharmacy@utah.gov